Local delivery of rapamycin: A toxicity and efficacy study in an experimental malignant glioma model in rats

Neuro-Oncology

Volumn 13, Issue 7, 2011, Pages 700-709

  Tyler, Betty ^a   Wadsworth, Scott ^c   Recinos, Violette ^a   Mehta, Vivek ^a   Vellimana, Ananth ^a   Li, Khan ^a   Rosenblatt, Joel ^c   Do, Hiep ^c   Gallia, Gary L ^a   Siu, I Mei ^a   Wicks, Robert T ^a   Rudek, Michelle A ^b   Zhao, Ming ^b   Brem, Henry ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Advanced Technologies and Regenerative Medicine   (United States)

Author keywords

Glioma; Local delivery; Rapamycin; Sirolimus

Indexed keywords

PLACEBO; POLYCAPROLACTONE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GLIOBLASTOMA; IN VIVO CULTURE; NONHUMAN; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; NEOPLASMS, EXPERIMENTAL; POLYMERS; RADIOTHERAPY; RATS; RATS, INBRED F344; SIROLIMUS; SURVIVAL RATE;

EID: 80052714158     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor050     Document Type: Article

References (44)

1. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
2. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Invest. 1996;14:551-555.
3. Chang SM, Theodosopoulos P, Lamborn K, et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004;100:605-611. (Pubitemid 38124780)
4. Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer. 2000;82:1371-1380. (Pubitemid 30175900)
5. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg. 1988;68:1-17. (Pubitemid 18019126)
6. Tatter SB. Recurrent malignant glioma in adults. Curr Treat Options Oncol. 2002;3:509-524.
7. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
8. Lukas RV, Boire A, Nicholas MK. Emerging therapies for malignant glioma. Expert Rev Anticancer Ther. 2007;7:S29-S36.
9. Van Duyne GD, Standaert R, Schreiber SL. Anatomic structure of the rapamycin human immunophilin FKBP-12 complex. J Am Chem Soc. 1991;113:7433-7434.
10. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926-1933. (Pubitemid 41095185)
11. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol. 1992;51:84-90.
12. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7:1758-1764. (Pubitemid 32708646)
13. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314-10319. (Pubitemid 32803017)
14. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249-258. (Pubitemid 32947647)
15. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94:195-199. (Pubitemid 43151534)
16. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med. 2007;356:2271-2281.
17. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005;23:5314-5322. (Pubitemid 46206985)
18. Jiang W, Cazacu S, Xiang C, et al. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia. 2008;10:235-243. (Pubitemid 351337518)
19. Masri J, Bernath A, Martin J, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007;67:11712-11720.
20. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003;4:343-348. (Pubitemid 37491095)
21. Chang SM, Wen P, Cloughesy T, et al. North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-361. (Pubitemid 40980358)
22. Galanis E, Buckner JC, Maurer MJ, et al. North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-5304. (Pubitemid 46206983)
23. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep. 2006;8:58-70. (Pubitemid 43154265)
24. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
25. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol. 2005;74:77-86.
26. Chang SM, Kuhn J,Wen P, et al. North American Brain Tumor Consortium and the National Cancer Institute. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004;22:427-435. (Pubitemid 39619819)
27. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006;67:156-158. (Pubitemid 44305484)
28. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-2347. (Pubitemid 41115390)
29. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Med. 2008;5(1):e8.
30. Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60:643-650. (Pubitemid 47247276)
31. Guerin C, Laterra J, Hruban RH, Brem H, Drewes LR, Goldstein GW. The glucose transporter and blood-brain barrier of human brain tumors. Ann Neurol. 1990;28:758-765.
32. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55-57.
33. Sipos EP, Witham TF, Ratan R, et al. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model. Neurosurgery. 2001;48:392-400. (Pubitemid 32164880)
34. Wen PY, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of patients with brain tumors. J Neurooncol. 2006;80:313-332. (Pubitemid 44782910)
35. Swaisland H, Smith R, Farebrother J, Jaigh A.The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral dose of ZD1839 ('Iressa'), a selective epidermal growth factor receptor ryrosine kinase inhibitor (EGFR-TkI), in healthy male volunteers. In Proc Am Soc Clin Oncol. Orlando, FL. 2002.
36. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007;47:1430-1439. (Pubitemid 47624594)
37. Tanaka K, Sasayama T, Mizukawa K, et al. Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4- amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells. J Neurooncol. 2007;84:233-244.
38. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62:7291-7297. (Pubitemid 36025252)
39. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/2 mice. Proc Natl Acad Sci USA. 2001;98:10320-10325. (Pubitemid 32803018)
40. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997;57:4183-4186. (Pubitemid 27413419)
41. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
42. Fan QW, Cheng C, Knight ZA, et al. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal. 2009;2(55):ra4.
43. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65:7052-7058. (Pubitemid 41161231)
44. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508. (Pubitemid 43259931)